These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8184798)

  • 21. Hormone replacement therapy and osteoporosis.
    Drury R
    Ir Med J; 1997 Oct; 90(6):214, 216. PubMed ID: 9611918
    [No Abstract]   [Full Text] [Related]  

  • 22. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
    Yasui T; Uemura H; Tomita J; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
    Menopause; 2006; 13(4):651-9. PubMed ID: 16837887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New evidence of conjugated estrogen and 17beta-estradiol for treatment and prevention of osteoporosis].
    Kurabayashi T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():369-73. PubMed ID: 18161134
    [No Abstract]   [Full Text] [Related]  

  • 24. Estrogen therapy in postmenopausal osteoporosis. What we know and what we don't.
    Roux C
    Rev Rhum Engl Ed; 1997 Jun; 64(6):402-9. PubMed ID: 9513613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation.
    Sitruk-Ware R
    Climacteric; 2007 Oct; 10(5):358-70. PubMed ID: 17852138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy.
    Richman S; Edusa V; Fadiel A; Naftolin F
    Menopause; 2006; 13(1):148-55. PubMed ID: 16607111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss.
    McKeever C; McIlwain H; Greenwald M; Gupta N; Jayawardene S; Huels G; Roberts M
    Clin Ther; 2000 Jul; 22(7):845-57. PubMed ID: 10945511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.
    O'Sullivan AJ; Crampton LJ; Freund J; Ho KK
    J Clin Invest; 1998 Sep; 102(5):1035-40. PubMed ID: 9727072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal estradiol. A potentially improved method of hormone replacement.
    Judd HL
    J Reprod Med; 1994 May; 39(5):343-52. PubMed ID: 8064701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with Systen, a new transdermal form of hormone replacement therapy.
    Corson SL
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():36-44. PubMed ID: 8499958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
    Ichikawa J; Sumino H; Ichikawa S; Ozaki M
    Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoparticle delivery for transdermal HRT.
    Valenzuela P; Simon JA
    Maturitas; 2012 Sep; 73(1):74-80. PubMed ID: 22325243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone replacement therapy for osteoporosis prevention.
    Mansour D
    Br J Gen Pract; 1997 Jul; 47(420):462-3. PubMed ID: 9281881
    [No Abstract]   [Full Text] [Related]  

  • 36. Transdermal menopausal hormone therapy: delivery through skin changes the rules.
    Buster JE
    Expert Opin Pharmacother; 2010 Jun; 11(9):1489-99. PubMed ID: 20426703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen replacement. The evolving role of transdermal delivery.
    Lobo RA; Ettinger B; Hutchinson KA; Knopp RH; Lindsay R; Nachtigall LE; Santoro N; Studd J
    J Reprod Med; 1996 Oct; 41(10 Suppl):781-96. PubMed ID: 8913986
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
    Josse RG
    CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The resistable rise of transdermal prevention].
    Berrino F
    Epidemiol Prev; 1997; 21(2):87-8. PubMed ID: 9378187
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.